Sodium Thiosulfate for Brain Lymphoma

Phase 1 & 2

Waitlist Available

Led By Edward A Neuwelt

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from entry onto study until death from any cause, assessed at 2 years

Awards & highlights

Approved for 10 Other Conditions

No Placebo-Only Group

Summary

This trial is testing methotrexate, mannitol, rituximab, and carboplatin to treat primary central nervous system lymphoma. The drugs work in different ways to stop cancer growth. Giving them together may be effective.

Eligible Conditions

Brain Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from entry onto study until death or progression of disease, assessed at 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from entry onto study until death or progression of disease, assessed at 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from entry onto study until death or progression of disease, assessed at 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Event-free survival

Overall survival

Awards & Highlights

Approved for 10 Other Conditions

This treatment demonstrated efficacy for 10 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (rituximab, mannitol, methotrexate, carboplatin)Experimental Treatment6 Interventions

Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mannitol

FDA approved

Thiosulfuric acid

FDA approved

Methotrexate

FDA approved

Carboplatin

FDA approved